• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by TNF Pharmaceuticals Inc.

    11/14/24 2:24:58 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $TNFA alert in real time by email
    SC 13G/A 1 ef20038672_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    INFORMATION STATEMENT TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (b)

    (Amendment No. 1)*
     
    TNF Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Common Shares
    (Title of Class of Securities)
     
    62856X201
    (CUSIP Number)
     
    September 30, 2024
    (Date of Event Which Requires Filing of This Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    ☒
    Rule 13d-1 (b)
    ☐
    Rule 13d-1 (c)
    ☐
    Rule 13d-1 (d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. 62856X201
    13G
    Page 2 of 4 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Global X Management Company LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0 **
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0 **
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0 **
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA
     
     
     
     

    **
    See Item 4 of this Filing


    CUSIP No. 62856X201
    13G
    Page 3 of 4 Pages
    Item 1.

    (a)
    Name of Issuer
    TNF Pharmaceuticals, Inc.

    (b)
    Address of Issuer’s Principal Executive Offices
    855 N. Wolfe Street, Suite 623
    Baltimore, MD 21205
     
    Item 2

    (a).
    (b). (c). Name, Principal Business Address, and Citizenship of Persons Filing:

    (1) Global X Management Company LLC (“GXMC”)
    605 3rd Avenue, 43rd Floor
    New York, NY 10158
    Citizenship: DE

    (d)
    Title of Class of Securities
    Common Shares
     
    (e)
    CUSIP Number
    62856X201
     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e)
    ☒
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g)
    ☐
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h)
    ☐
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j)
    ☐
    Group, in accordance with §240.13d-1(b)(1)(ii)(J).


    CUSIP No. 62856X201
    13G
    Page 4 of 4 Pages
    Item 4.
    Ownership.
    The information in items 1 and 5 through 11 on the cover page (p. 2 ) on Schedule 13G is hereby incorporated by reference.

    Item 5.
    Ownership of Five Percent or Less of a Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    Not Applicable.

    Item 8.
    Identification and Classification of Members of the Group.
    Not Applicable.

    Item 9.
    Notice of Dissolution of Group.
    Not Applicable.

    Item 10.
    Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Global X Management Company LLC
    By: /s/ Ryan O’Connor
    Name/Title: Ryan O’Connor, Chief Executive Officer
    Date: November 14, 2024



    Get the next $TNFA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TNFA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $TNFA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol "QCLS"

    Licensed technology positions Company at forefront of new quantum-class computing paradigm Q/C Technologies, Inc. (NASDAQ:QCLS), formerly TNF Pharmaceuticals, Inc. (NASDAQ: TNFA), ("Q/C" or "the Company"), today announced that its common stock will begin trading under the new ticker symbol "QCLS" beginning today at the market open. The Company's new name Q/C Technologies represents its recent strategic pivot into quantum-class computing with exclusive global rights to LightSolver's light-speed laser processing unit (LPU), the world's first light and laser-based computing system, for application in quantum class cryptocurrency verticals. "The official transition to Q/C Technologies and

    9/25/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol "QCLS" to Reflect Strategic Focus on Quantum Class Photonic Computing

    New trading symbol QCLS effective Thursday, September 25, 2025 Licensed technology positions Company at forefront of new quantum-class computing paradigm TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("Q/C" or the "Company") today announced that it has changed its corporate name to Q/C Technologies, Inc. and will begin trading under the new ticker symbol "QCLS" on the Nasdaq Capital Market, effective as of the market open on Thursday, September 25, 2025. Until then, the Company's common stock will continue to trade under its current ticker symbol "TNFA." The new name Q/C Technologies represents the Company's recent strategic pivot into quantum-class computing with exclusive global rights to

    9/24/25 9:15:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

    TNF Pharmaceuticals Inc. (NASDAQ:TNFA), ("TNF" or the "Company") today announced that it received written notice from the Nasdaq Stock Market on September 16, 2025, confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2). To regain compliance with the Listing Rule, the Company's shares maintained the minimum bid price of $1.00 for 10 consecutive business days. "We are pleased to have regained compliance with Nasdaq's listing standards. This milestone comes as we work to build a strong strategic platform for growth and shareholder value. We will be updating shareholders on our progress in the weeks ahead,"

    9/17/25 9:24:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    SEC Filings

    View All

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    9/26/25 5:10:36 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    TNF Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/10/25 5:00:34 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: TNF Pharmaceuticals Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - TNF Pharmaceuticals, Inc. (0001321834) (Filer)

    9/5/25 5:30:47 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Vice President, Finance Rauch Gary M

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:15 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by President, CMO Glass Mitchell

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:12 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Interim CFO Rhodes Ian

    4 - TNF Pharmaceuticals, Inc. (0001321834) (Issuer)

    4/18/25 4:30:14 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Financials

    Live finance-specific insights

    View All

    TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025

    Concurrent clinical studies underway evaluating novel TNF-alpha inhibitor for treating muscle loss associated with hip/femur fracture repair, GLP-1 weight loss Investors invited to submit questions prior to the event TNF Pharmaceuticals, Inc. (NASDAQ:TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it will host an investor conference call and webcast on Thursday, March 6, 2025, at 4:30 pm ET. Mitchell Glass, M.D., President and Chief Medical Officer of TNF, will provide a clinical scientific update on the Company's lead candidate isomyosamine, a novel oral TNF

    3/5/25 9:00:00 AM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $TNFA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TNF Pharmaceuticals Inc.

    SC 13G/A - TNF Pharmaceuticals, Inc. (0001321834) (Subject)

    11/14/24 2:24:58 PM ET
    $TNFA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care